Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $7.18B
• Dividend Yield: N/A
• Average Volume (3M): 999.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.31
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.38
• Shares Outstanding: 77,828,920
• 10 Day Avg. Volume: 1,034,726
• 30 Day Avg. Volume: 999,494
• PEG Ratio: 0.14
• Price to Book (P/B): 10.98
• Price to Sales (P/S): 41.30
• P/FCF Ratio: -2.88
• Enterprise Value/Market Cap: 0.07
• Enterprise Value/Revenue: 54.49
• Enterprise Value/Gross Profit: 54.49
• Enterprise Value/Ebitda: -2.27
• 1Y Price Target: $121.25
• Price Target Upside: 34.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 52 Neutral
• Price Target: $93.00 ▲(2.80% Upside)

The overall stock score of 52 reflects significant financial challenges, including ongoing losses and high leverage, which weigh heavily on the company's outlook. However, positive technical indicators suggest potential short-term momentum, partially offsetting the financial concerns. The lack of profitability and dividend yield further impacts the valuation negatively.

Positive Factors

Clinical Trial Success

Successful Phase 3 trial results for obefazimod in ulcerative colitis strengthen Abivax's position in the biotech sector, potentially leading to future commercialization and partnerships.

Major Funding Secured

The significant capital raised through the public offering enhances Abivax's financial stability, supporting its R&D efforts and long-term strategic goals.

R&D Expansion

Increased investment in R&D and team expansion positions Abivax to advance its pipeline, potentially leading to new therapies and market opportunities.

Negative Factors

High Operating Losses

Rising operating losses indicate ongoing financial challenges, which may hinder Abivax's ability to sustain operations without continuous external funding.

Negative Cash Flow

Negative cash flow from operations suggests liquidity risks, requiring Abivax to rely on external financing, impacting long-term financial health.

High Leverage

High leverage limits financial flexibility and increases risk, potentially affecting Abivax's ability to invest in growth and manage economic downturns.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

How the Company Makes Money

Abivax generates revenue primarily through funding from investors and partnerships in the biopharmaceutical industry. The company does not currently have commercial revenue from product sales, as it is still in the clinical development phase. Its revenue model is primarily reliant on securing grants, collaborations, and potential licensing agreements with larger pharmaceutical companies. Successful clinical trial outcomes can lead to milestone payments and royalties from partnerships, which can significantly contribute to its financial resources as it progresses towards commercialization.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While revenue is growing, profitability remains a concern with high operating losses and negative cash flows. These factors underscore the need for strategic improvements to enhance financial stability.

Income Statement

The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.

Cash Flow

Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.42M	10.79M	4.62M	4.58M	37.00K	63.00K
Gross Profit	9.42M	10.79M	4.57M	4.47M	-119.00K	-33.77M
EBITDA	-225.56M	-171.88M	-133.21M	-53.31M	-38.59M	-38.00M
Net Income	-195.39M	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	119.64M	205.23M	327.06M	75.54M	109.23M	71.30M
Cash, Cash Equivalents and Short-Term Investments	60.95M	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	98.71M	97.36M	55.46M	49.23M	51.65M	33.99M
Total Liabilities	167.92M	164.64M	131.05M	68.36M	83.30M	53.40M
Stockholders Equity	-48.28M	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-135.98M	-154.72M	-100.28M	-54.26M	-47.30M	-30.72M
Operating Cash Flow	-135.51M	-154.07M	-100.01M	-53.94M	-45.66M	-29.82M
Investing Cash Flow	2.42M	15.76M	-10.49M	-12.03M	-1.46M	-575.00K
Financing Cash Flow	-28.72M	28.21M	340.57M	32.21M	78.51M	49.93M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 90.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 90.47 is above the 20-day moving average (MA) of 89.19, above the 50-day MA of 84.11, and above the 200-day MA of 31.22, indicating a bullish trend. The MACD of 2.91 indicates Positive momentum. The RSI at 56.97 is Neutral, neither overbought nor oversold. The STOCH value of 31.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RYTM	55 Neutral	$7.25B	―	-1334.54%	―	53.55%	30.87%
ABVX	52 Neutral	$7.18B	―	―	―	―	18.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	51 Neutral	$5.93B	―	-29.71%	―	74.86%	-13.23%
RNA	50 Neutral	$7.16B	―	-37.76%	―	1.23%	-20.45%
CYTK	49 Neutral	$6.55B	―	―	―	2635.74%	4.66%
NUVL	43 Neutral	$7.01B	―	-43.55%	―	―	-76.16%

Abivax SA Sponsored ADR Corporate Events

Abivax Reports Increased Losses but Secures Major Funding in H1 2025

On September 8, 2025, Abivax SA announced its financial results for the first half of 2025, revealing a significant increase in operating loss to EUR 93.7 million compared to the same period in 2024. The increase was driven by higher research and development expenses, particularly related to the company’s Crohn’s Disease clinical program and the expansion of its R&D team. Despite a decrease in sales and marketing expenses, the company’s net financial position deteriorated, with a cash position of EUR 60.9 million as of June 30, 2025, down from EUR 144.2 million at the end of 2024. However, Abivax successfully completed a public offering in July 2025, raising approximately EUR 597.2 million in net proceeds, which is expected to support its ongoing clinical programs and operational goals.

Abivax SA Announces $608.6 Million Public Offering of ADSs

On July 23, 2025, Abivax SA entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co., and Guggenheim Securities, LLC for a public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per share. The offering is expected to generate approximately $608.6 million in net proceeds, with the closing anticipated on July 28, 2025. This move is part of Abivax’s strategy to strengthen its financial position and support its ongoing research and development efforts, potentially enhancing its market presence and stakeholder value.